INPLASY202210008

Clinical Benefits of Immune Checkpoint Inhibitors and Predictive Value of Tumor Mutation Burden in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Keywords: hepatocellular carcinoma; immunotherapy; immune checkpoint inhibitor; PD-1/PD-L1; anti-VEGF; tumor mutation burden; atezolizumab; sintilimab.

Download PDF - 202210008

Review Status: Ongoing